A pilot trial of doxorubicin containing phosphatidyldiglycerol based thermosensitive liposomes in spontaneous feline soft tissue sarcoma

References

• Martano M, Morello E, Buracco P. (2011). Feline injection-site sarcoma: past, present and future perspectives. Vet J 188:136–41.
   PubMed Web of Science ®Google Scholar
• Ladlow J. (2013). Injection site-associated sarcoma in the cat: treatment recommendations and results to date. J Feline Med Surg 15:409–18.
   PubMed Web of Science ®Google Scholar
• Zardo KM, Damiani LP, Matera JM, et al. (2016). Recurrent and non-recurrent feline injection site sarcoma: computed tomographic and ultrasonographic findings. J Feline Med Surg 18:773–82.
   PubMed Web of Science ®Google Scholar
• Romanelli G, Marconato L, Olivero D, et al. (2008). Analysis of prognostic factors associated with injection-site sarcomas in cats: 57 cases (2001–2007). J Am Vet Med Assoc 232:1193–9.
   PubMed Web of Science ®Google Scholar
• McEntee MC, Page RL. (2001). Feline vaccine-associated sarcomas. J Vet Intern Med 15:176–82.
   PubMed Web of Science ®Google Scholar
• Phelps HA, Kuntz CA, Milner RJ, et al. (2011). Radical excision with five-centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998–2002). J Am Vet Med Assoc 239:97–106.
   PubMed Web of Science ®Google Scholar
• Davidson EB, Gregory CR, Kass PH. (1997). Surgical excision of soft tissue fibrosarcomas in cats. Vet Surg 26:265–9.
   PubMed Web of Science ®Google Scholar
• Eckstein C, Guscetti F, Roos M, et al. (2009). A retrospective analysis of radiation therapy for the treatment of feline vaccine-associated sarcoma. Vet Comp Oncol 7:54–68.
   PubMed Web of Science ®Google Scholar
• Cohen M, Wright JC, Brawner WR, et al. (2001). Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996–2000). J Am Vet Med Assoc 219:1582–9.
   PubMed Web of Science ®Google Scholar
• Poirier VJ, Thamm DH, Kurzman ID, et al. (2002). Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med 16:726–31.
   PubMed Web of Science ®Google Scholar
• O'Keefe DA, Sisson DD, Gelberg HB, et al. (1993). Systemic toxicity associated with doxorubicin administration in cats. J Vet Intern Med 7:309–17.
   PubMed Web of Science ®Google Scholar
• Kent MS. (2013). Cats and chemotherapy: treat as 'small dogs' at your peril. J Feline Med Surg 15:419–24.
   PubMed Web of Science ®Google Scholar
• Reiman RA, Mauldin GE, Neal Mauldin G. (2008). A comparison of toxicity of two dosing schemes for doxorubicin in the cat. J Feline Med Surg 10:324–31.
   PubMed Web of Science ®Google Scholar
• Barber LG, Sørenmo KU, Cronin KL, Shofer FS. (2000). Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma. J Am Anim Hosp Assoc 36:416–21.
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Wigler N, Inbar M, et al. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–9.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Mohammadtaghi S, Uster PS, et al. (2001). Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7:243–54.
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, et al. (2010). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11:561–70.
   PubMed Web of Science ®Google Scholar
• Issels RD. (2008). Hyperthermia adds to chemotherapy. Eur J Cancer 44:2546–54.
   PubMed Web of Science ®Google Scholar
• Issels R, Kampmann E, Kanaar R, Lindner LH. (2016). Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application. Int J Hyperthermia 32:89–95.
   PubMed Web of Science ®Google Scholar
• Hauck ML, LaRue SM, Petros WP, et al. (2006). Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumours. Clin Cancer Res 12:4004–10.
   PubMed Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, et al. (2012). Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumours. Cancer Res 72:5566–75.
   PubMed Web of Science ®Google Scholar
• Kneidl B, Peller M, Winter G, et al. (2014). Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomed 9:4387–98.
   PubMed Web of Science ®Google Scholar
• Needham D, Anyarambhatla G, Kong G, Dewhirst MW. (2000). A new temperature-sensitive liposome for use with mild hyperthermia: characterisation and testing in a human tumour xenograft model. Cancer Res 60:1197–201.
   PubMed Web of Science ®Google Scholar
• Limmer S, Hahn J, Schmidt R, et al. (2014). Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes. Pharm Res 31:2276–86.
   PubMed Web of Science ®Google Scholar
• Li L, Hagen TLM. Schipper D, et al. (2010). Triggered content release from optimised stealth thermosensitive liposomes using mild hyperthermia. J Control Release 143:274–9.
   PubMed Web of Science ®Google Scholar
• Poon RT, Borys N. (2011). Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 7:937–45.
   PubMed Web of Science ®Google Scholar
• Wood BJ, Poon RT, Locklin JK, et al. (2012). Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol 23:248.
   PubMed Web of Science ®Google Scholar
• Zagar TM, Vujaskovic Z, Formenti S, et al. (2014).Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pre-treated patients with local regionally recurrent breast cancer. Int J Hyperthermia 30:285–94.
   PubMed Web of Science ®Google Scholar
• Lindner LH, Eichhorn ME, Eibl H, et al. (2004). Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 10:2168–78.
   PubMed Web of Science ®Google Scholar
• Hossann M, Wiggenhorn M, Schwerdt A, et al. (2007). In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta 1768:2491–9.
   PubMed Web of Science ®Google Scholar
• Hossann M, Wang T, Wiggenhorn M, et al. (2010). Size of thermosensitive liposomes influences content release. J Control Release 147:436–43.
   PubMed Web of Science ®Google Scholar
• Hossann M, Syunyaeva Z, Schmidt R, et al. (2012). Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release 162:400–6.
   PubMed Web of Science ®Google Scholar
• Willerding L, Limmer S, Hossann M, et al. (2016). Method of hyperthermia and tumour size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumours. J Control Release 222:47–55.
   Web of Science ®Google Scholar
• Peller M, Willerding L, Limmer S, et al. (2016). Surrogate MRI markers for hyperthermia-induced release of doxorubicin from thermosensitive liposomes in tumours. J Control Release 237:138–46.
   PubMed Web of Science ®Google Scholar
• VCOG. (2011). Veterinary cooperative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. [Epub ahead of print]. doi: 10.1111/j.1476-5829.2011.00283.x.
   Google Scholar
• Bruggmoser G, Bauchowitz S, Canters R, et al. (2012). Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia. Strahlentherapie Und Onkologie 188:198–211.
   PubMed Web of Science ®Google Scholar
• Gong W, Wang Z, Liu N, et al. (2011). Improving efficiency of adriamycin crossing blood brain barrier by combination of thermosensitive liposomes and hyperthermia. Biol. Pharm. Bull 34:1058–64.
   PubMed Web of Science ®Google Scholar
• Zutphen LFM. (1995). Grundlagen der Versuchstierkunde Ein Beitrag zum tierschutzgerechten Umgang mit Versuchstieren und zur Qualität tierexperimenteller Ergebnisse; mit 38 Tabellen. Stuttgart, Jena, New York: G. Fischer, 341 p. ISBN: 9783437205323.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000). New guidelines to evaluate the response to treatment in solid tumours. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–16.
   PubMed Web of Science ®Google Scholar
• Schramm N, Englhart E, Schlemmer M, et al. (2013). Tumour response and clinical outcome in metastatic gastrointestinal stromal tumours under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria. Eur J Radiol 82:951–8.
   PubMed Web of Science ®Google Scholar
• Heußel CP, Meier S, Wittelsberger S, et al. (2007). Quantitative CT-Verlaufskontrolle von Lebermalignomen nach RECIST und WHO im Vergleich zur Volumetrie [Follow-Up CT Measurement of Liver Malignoma According to RECIST and WHO vs. Volumetry]. Fortschr Röntgenstr 179:958–64.
   PubMedGoogle Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. (2009). From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumours. J Nucl Med 50:1122–50.
   Web of Science ®Google Scholar
• Szebeni J, Muggia F, Gabizon A, Barenholz Y. (2011). Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev 63:1020–30.
   PubMed Web of Science ®Google Scholar
• Haubner F, Ohmann E, Pohl F, et al. (2012). Wound healing after radiation therapy: review of the literature. Radiat Oncol 7:162.
   PubMed Web of Science ®Google Scholar
• Allen TM. (2007). Pharmacokinetics and biopharmaceutics of lipid-based drug formulations. In: Gregoriadis G, ed. Interactions of liposomes with the biological milieu. New York; Liposome Technology, 49–64, ISBN: 9780849397257.
   Google Scholar
• Zamboni WC, Ramalingam S, Friedland DM, et al. (2009). Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 15:1466–72.
   PubMed Web of Science ®Google Scholar
• Baur A, Stäbler A, Wendtner CM, et al. (2003). MR-imaging changes of musculoskeletal soft-tissue sarcomas associated with neoadjuvant chemotherapy and hyperthermia. Int J Hyperthermia 19:391–401.
   PubMed Web of Science ®Google Scholar